Disability and health-related quality of life in outpatients with generalised anxiety disorder treated in psychiatric clinics: Is there still room for improvement?

Annals of General Psychiatry

Volumn 10, Issue , 2011, Pages

  Bobes, Julio ^a   Caballero, Luis ^b   Vilardaga, Inma ^c   Rejas, Javier ^d  

^a UNIVERSITY OF OVIEDO   (Spain)

^b HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^c European Biometrics Institute   (Spain)

^d PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; AMITRIPTYLINE; BENTAZEPAM; BROMAZEPAM; CITALOPRAM; CLOMIPRAMINE; CLONAZEPAM; CLORAZEPATE DIPOTASSIUM; DIAZEPAM; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; GABAPENTIN; HALAZEPAM; IMIPRAMINE; KETAZOLAM; LORAZEPAM; LORMETAZEPAM; MAPROTILINE; MEDAZEPAM; MIRTAZAPINE; PAROXETINE; PREGABALIN; SERTRALINE; SULPIRIDE; TOPIRAMATE; TRAZODONE; UNINDEXED DRUG; VENLAFAXINE;

ADULT; AGED; ARTICLE; DISABILITY; FEMALE; GENERALIZED ANXIETY DISORDER; HUMAN; MALE; OUTPATIENT DEPARTMENT; PREVALENCE; QUALITY OF LIFE; SEX DIFFERENCE;

EID: 79952525985     PISSN: None     EISSN: 1744859X     Source Type: Journal    
DOI: 10.1186/1744-859X-10-7     Document Type: Article

References (55)

1. Wittchen HU. Generalized anxiety disorder: prevalence, burden and cost to society. Depress Anxiety 2002, 16:162-171. 10.1002/da.10065, 12497648.
2. Barsky AJ, Orav EJ, Bates DW. Somatization increases medical utilization and costs independent of psychiatric and medical comorbidity. Arch Gen Psychiatry 2005, 62:903-910. 10.1001/archpsyc.62.8.903, 16061768.
3. McLaughlin TP, Khandker RK, Kruzikas DT, Tummala R. Overlap of anxiety and depression in a managed care population: Prevalence and association with resource utilization. J Clin Psychiatry 2006, 67:1187-1193. 10.4088/JCP.v67n0803, 16965195.
4. Lépine JP. The epidemiology of anxiety disorders: prevalence and societal costs. J Clin Psychiatry 2002, 63(Suppl 14):4-8.
5. Kroenke K, Spitzer RL, Williams JB, Monahan PO, Löwe B. Anxiety disorders in primary care: prevalence, impairment, comorbidity, and detection. Ann Intern Med 2007, 146:317-325.
6. Sareen J, Jacobi F, Cox BJ, Belik SL, Clara I, Stein MB. Disability and poor quality of life associated with comorbid anxiety disorders and physical conditions. Arch Intern Med 2006, 166:2109-2116. 10.1001/archinte.166.19.2109, 17060541.
7. Reich J, Perry JC, Shera D, Dyck I, Vasile R, Goisman RM, Rodriguez-Villa F, Massion AO, Keller M. Comparison of personality disorders in different anxiety disorder diagnoses: panic, agoraphobia, generalized anxiety, and social phobia. Ann Clin Psychiatry 1994, 6:125-134. 10.3109/10401239409148991, 7804388.
8. Kessler RC, Chiu WT, Demler O, Walters EE. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005, 62:617-627. 10.1001/archpsyc.62.6.617, 2847357, 15939839.
9. Ruscio AM, Chiu WT, Roy-Byrne P, Stang PE, Stein DJ, Wittchen HU, Kessler RC. Broadening the definition of generalized anxiety disorder: effects on prevalence and associations with other disorders in the National Comorbidity Survey Replication. J Anxiety Disord 2007, 21:662-676. 10.1016/j.janxdis.2006.10.004, 2475335, 17118626.
10. Kendler KS, Walters EE, Neale MC, Kessler RC, Heath AC, Eaves LJ. The structure of the genetic and environmental risk factors for six major psychiatric disorders in women. Phobia, generalized anxiety disorder, panic disorder, bulimia, major depression, and alcoholism. Arch Gen Psychiatry 1995, 52:374-383.
11. Wittchen HU, Hoyer J. Generalized anxiety disorder: nature and course. J Clin Psychiatry 2001, 62(Suppl 11):15-19.
12. Haro JM, Palacín C, Vilagut G, Martínez M, Bernal M, Luque I, Codony M, Dolz M, Alonso J, . Grupo ESEMeD-España Prevalence of mental disorders and associated factors: results from the ESEMeD-Spain study. Med Clin (Barc) 2006, 126:445-451. 10.1157/13086324, 16620730, Grupo ESEMeD-España.
13. Lépine JP, Gasquet I, Kovess V, Arbabzadeh-Bouchez S, Nègre-Pagès L, Nachbaur G, Gaudin AF. Prevalence and comorbidity of psychiatric disorders in the French general population. Encephale 2005, 31:182-194.
14. Haro JM, Palacín C, Vilagut G, Romera B, Codony M, Autonell J, Ferrer M, Ramos J, Kessler R, Alonso J. Epidemiology of mental disorders in Spain: methods and participation in the ESEMeD-Spain project. Actas Esp Psiquiatr 2003, 31:182-191.
15. Tyrer P, Baldwin D. Generalised anxiety disorder. Lancet 2006, 368:2156-2166. 10.1016/S0140-6736(06)69865-6, 17174708.
16. Brawman-Mintzer O, Lydiard RB, Crawford MM, Emmanuel N, Payeur R, Johnson M, Knapp RG, Ballenger JC. Somatic symptoms in generalized anxiety disorder with and without comorbid psychiatric disorders. Am J Psychiatry 1994, 151:930-932.
17. Kessler RC, Berglund PA, Dewit DJ, Ustün TB, Wang PS, Wittchen HU. Distinguishing generalized anxiety disorder from major depression: prevalence and impairment from current pure and comorbid disorders in the US and Ontario. Int J Methods Psychiatr Res 2002, 11:99-111. 10.1002/mpr.128, 12459823.
18. McHorney CA, Ware JE, Raczek AE. The MOS 36-Item Short-Form Health Survey (SF-36), II: psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care 1993, 31:247-263. 10.1097/00005650-199303000-00006, 8450681.
19. Stein DJ, Matsunaga H. Cross-cultural aspects of social anxiety disorder. Psychiatr Clin North Am 2001, 24:773-782. 10.1016/S0193-953X(05)70262-8, 11723632.
20. Sara SJ, Hars B. In memory of consolidation. Learn Mem 2006, 13:515-521. 10.1101/lm.338406, 17015848.
21. Boulenger JP, Capdevielle D. Pharmacological treatment of generalized anxiety disorders: rationale and limitations. Encephale 2007, 33:84-94. 10.1016/S0013-7006(07)91562-6, 17457298.
22. Fernández A, Haro JM, Codony M, Vilagut G, Martínez-Alonso M, Autonell J, Salvador-Carulla L, Ayuso-Mateos JL, Fullana MA, Alonso J. Treatment adequacy of anxiety and depressive disorders: primary versus specialised care in Spain. J Affect Disord 2006, 96:9-20.
23. Saarni SI, Suvisaari J, Sintonen H, Pirkola S, Koskinen S, Aromaa A, Lönnqvist J. Impact of psychiatric disorders on health-related quality of life: general population survey. Br J Psychiatry 2007, 190:326-332. 10.1192/bjp.bp.106.025106, 17401039.
24. Hoffman DL, Dukes EM, Wittchen HU. Human and economic burden of generalized anxiety disorder. Depress Anxiety 2008, 25:72-90. 10.1002/da.20257, 17146763.
25. Bobes J, González MP, Bascarán MT, Arango C, Sáiz PA, Bousoño M. Quality of life and disability in patients with obsessive-compulsive disorder. Eur Psychiatry 2001, 16:239-245. 10.1016/S0924-9338(01)00571-5, 11418275.
26. Lenox-Smith AJ, Reynolds A. A double-blind, randomised, placebo controlled study of venlafaxine XL in patients with generalised anxiety disorder in primary care. Br J Gen Pract 2003, 53:772-777. 1314709, 14601352.
27. Lobo A, Campos R. Los trastornos de ansiedad en atención primaria 1997, Madrid, Spain: EMISA.
28. The ESEMeD/MHEDEA 2000 investigators Prevalence of mental disorders in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatr Scand 2004, 109(Suppl 420):21-27. The ESEMeD/MHEDEA 2000 investigators.
29. Bruce SE, Machan JT, Dyck I, Keller MB. Infrequency of "pure" GAD: impact of psychiatric comorbidity on clinical course. Depress Anxiety 2001, 14:219-225. 10.1002/da.1070, 11754129.
30. Pollack MH, Zaninelli R, Goddard A, McCafferty JP, Bellew KM, Burnham DB, Iyengar MK. Paroxetine in the treatment of generalized anxiety disorder: results of a placebo-controlled, flexible-dosage trial. J Clin Psychiatry 2001, 62:350-357. 10.4088/JCP.v62n0508, 11411817.
31. Caballero L, Bobes J, Vilardaga I, Rejas J. Clinical prevalence and reason for visit of patients with generalized anxiety disorder seen in the psychiatry out-patient clinics in Spain. Results of the LIGANDO study. Actas Esp Psiquiatr 2009, 37:17-20.
32. World Health Organization The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Description and Diagnostic Guidelines 1992, Geneva, Switzerland: World Health Organization, World Health Organization.
33. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders 1994, Washington, DC: American Psychiatric Association, 4, American Psychiatric Association.
34. World Health Organization The Anatomical Therapeutic Chemical Classification System 1991, Geneva, Switzerland: World Health Organization, World Health Organization.
35. Hamilton M. Diagnosis and rating of anxiety. Br J Psychiatry 1969, (Special):76-79.
36. Guy W. Clinical Global Impression (CGI). ECDEU Assessment Manual for Psychopharmacology 1976, 218-221. Rockville, MD: National Institute of Mental Health.
37. Sheehan DV, Harnett-Sheehan K, Raj BA. The measurement of disability. Int Clin Psychopharmacol 1996, 11(Suppl 3):89-95. 10.1097/00004850-199606003-00015, 8923116.
38. Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992, 30:473-483. 10.1097/00005650-199206000-00002, 1593914.
39. Sackets D, Rosenberg W, Gray J, Haynes RB, Richardson WS. Evidence based medicine: what it is and what it isn't. BMJ 1996, 312:71-72. 2349778, 8555924.
40. Canadian Psychiatric Association Clinical Practice Guidelines: Management of Anxiety Disorders. Can J Psychiatry 2006, 51(Suppl 2):9S-91S. Canadian Psychiatric Association.
41. Guía de Prescripción Terapéutica Agencia española de medicamentos y productos sanitarios 2006, Barcelona, Spain: Ministerio de Sanidad y Consumo, Pharma Editores, Guía de Prescripción Terapéutica.
42. Martin JL, Sainz-Pardo M, Furukawa TA, Martin-Sanchez E, Seoane T, Galan C. Benzodiazepines in generalized anxiety disorder: heterogeneity of outcomes based on a systematic review and meta-analysis of clinical trials. J Psychopharmacol 2007, 21:774-782. 10.1177/0269881107077355, 17881433.
43. Jorgensen TR, Stein DJ, Despiegel N, Drost PB, Hemels ME, Baldwin DS. Cost-effectiveness analysis of escitalopram compared with paroxetine in treatment of generalized anxiety disorder in the United Kingdom. Ann Pharmacother 2006, 40:1752-1758. 10.1345/aph.1H156, 16985090.
44. Allgulander C, Jørgensen T, Wade A, François C, Despiegel N, Auquier P, Toumi M. Health-related quality of life (HRQOL) among patients with Generalised Anxiety Disorder: evaluation conducted alongside an escitalopram relapse prevention trial. Curr Med Res Opin 2007, 23:2543-2549. 10.1185/030079907X226087, 17825130.
45. Ohayon MM, Caulet M, Lemoine P. Comorbidity of mental and insomnia disorders in the general population. Compr Psychiatry 1998, 39:185-197. 10.1016/S0010-440X(98)90059-1, 9675502.
46. Mellman TA. Sleep and anxiety disorders. Psychiatr Clin North Am 2006, 29:1047-1058. 10.1016/j.psc.2006.08.005, 17118281.
47. Stewart R, Besset A, Bebbington P, Brugha T, Lindesay J, Jenkins R, Singleton N, Meltzer H. Insomnia comorbidity and impact and hypnotic use by age group in a national survey population aged 16 to 74 years. Sleep 2006, 29:1391-1397.
48. Means-Christensen AJ, Roy-Byrne PP, Sherbourne CD, Craske MG, Stein MB. Relationships among pain, anxiety, and depression in primary care. Depress Anxiety 2007, 10:1-8.
49. Pinto-Meza A, Serrano-Blanco A, Codony M, Reneses B, von Korff M, Haro JM, Alonso J. Prevalence and physical-mental comorbidity of chronic back and neck pain in Spain: results from the ESEMeD Study [in Spanish]. Med Clin (Barc) 2006, 127:325-330. 10.1157/13092313, 16987451.
50. Breivik H, Collett B, Ventafridda V, Cohen R, Gallacher D. Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. Eur J Pain 2006, 10:287-333. 10.1016/j.ejpain.2005.06.009, 16095934.
51. Breitholtz E, Johansson B, Ost LG. Cognitions in generalized anxiety disorder and panic disorder patients. A prospective approach. Behav Res Ther 1999, 37:533-544. 10.1016/S0005-7967(98)00147-8, 10372467.
52. Mantella RC, Butters MA, Dew MA, Mulsant BH, Begley AE, Tracey B, Shear MK, Reynolds CF, Lenze EJ. Cognitive impairment in late-life generalized anxiety disorder. Am J Geriatr Psychiatry 2007, 15:673-679. 10.1097/JGP.0b013e31803111f2, 17426260.
53. Fabre LF, Putman HP. Depressive symptoms and intellectual functioning in anxiety patients treated with clorazepate. J Clin Psychiatry 1988, 49:189-192.
54. Meoni P, Salinas E, Brault Y, Hackett D. Pattern of symptom improvement following treatment with venlafaxine XR in patients with generalized anxiety disorder. J Clin Psychiatry 2001, 62:888-893. 10.4088/JCP.v62n1109, 11775049.
55. Ballenger JC, Davidson JR, Lecrubier Y, Nutt DJ, Borkovec TD, Rickels K, Stein DJ, Wittchen H-U. Consensus statement on generalized anxiety disorder from the international consensus group on depression and anxiety. J Clin Psychiatry 2001, 62(Suppl 11):53-58.